Royalty Pharma plc reported impressive financial results for Q4 2025, with Portfolio Receipts of $874 million and full-year Portfolio Receipts of $3,254 million, reflecting 18% and 16% growth, respectively. The company also provided guidance for 2026, expecting Portfolio Receipts between $3,275 million and $3,425 million, with 3-8% growth in Royalty Receipts.
The company’s strong performance was driven by double-digit growth in Royalty Receipts, with increases in products like Voranigo, Trelegy, Tremfya, and the cystic fibrosis franchise. Royalty Pharma’s balanced capital allocation approach included deploying $2.6 billion in 2025, repurchasing 37 million Class A shares, and increasing the quarterly dividend by 7% in Q1 2026.
Positive clinical and regulatory updates in 2025 included FDA approvals for Cytokinetics’ Myqorzo and Johnson & Johnson’s Tremfya, as well as positive Phase 3 results for Teva’s TEV-‘749, Gilead’s Trodelvy, and other therapies. Royalty Pharma’s 2026 financial outlook anticipates continued growth, with Portfolio Receipts expected to be between $3,275 million and $3,425 million.
Royalty Pharma’s liquidity and capital resources remain strong, with cash and cash equivalents of $619 million as of December 31, 2025. The company paid dividends of $512 million in 2025, repurchased $1.2 billion in Class A shares, and announced a new share repurchase program of up to $3.0 billion. Adjusted EBITDA for Q4 2025 was $816 million, reflecting the company’s solid financial performance.
In terms of capital deployment, Royalty Pharma invested $887 million in Q4 2025, primarily in upfront payments for new royalty transactions and research and development funding. Recent transactions include agreements with Teva Pharmaceuticals, PTC Therapeutics, and Denali Therapeutics. The company’s portfolio includes royalties on over 35 commercial products and 20 development-stage candidates, positioning Royalty Pharma as a key player in the biopharmaceutical industry.
Read more at GlobeNewswire: Royalty Pharma Reports Q4 and Full Year 2025 Results